Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 9/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL337463 | 0.83 | EGLN1 (0.62) | EGLN1HIF1AKMT2AMEN1 | |
| SCHEMBL10080878 | 0.83 | EGLN1 (0.58) | EGLN1HTTALDH1A1HIF1AHDAC6 | |
| SCHEMBL336625 | 0.81 | EGLN1 (0.59) | EGLN1HIF1ALMNA | |
| SCHEMBL336821 | 0.81 | EGLN1 (0.61) | EGLN1HIF1AKMT2AMEN1 | |
| SCHEMBL336409 | 0.80 | EGLN1 (0.58) | EGLN1HIF1ALMNA | |
| SCHEMBL337462 | 0.79 | EGLN1 (0.65) | EGLN1HIF1AKMT2AMEN1 | |
| SCHEMBL337429 | 0.77 | EGLN1 (0.56) | EGLN1ALDH1A1HIF1AKMT2ATSHR | |
| SCHEMBL336893 | 0.76 | EGLN1 (0.77) | EGLN1HIF1AKMT2AMEN1 | |
| SCHEMBL344905 | 0.76 | EGLN1 (0.53) | EGLN1HIF1A | |
| SCHEMBL336885 | 0.75 | EGLN1 (0.64) | EGLN1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | claimed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | claimed |
| US-8097620-B2 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | AMGEN INC. (US) | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099171-A1 | Diazaquinolones that inhibit prolyl hydroxylase activity | EGLN3, EGLN2, HIF1AN | EGLN1 4/4885HTT 1619/4885ALDH1A1 108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.